BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:45 PM
Oct 21, 2009
 |  BC Extra  |  Company News

NICE rebuffs Tyverb again

The U.K.'s NICE issued a new preliminary appraisal recommending against the use of Tyverb lapatinib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in combination with capecitabine...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >